1 September 2016 Oryzon Genomics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference and at BioPharm America 2016
8 August 2016 ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2016
5 July 2016 Oryzon nominates ORY-3001, a specific LSD1 inhibitor, next drug candidate to enter preclinical development in non-oncological indications